2026-526022-41-00招募中1 期
A double-blind, prospective, randomised, placebo-controlled, single-centre, proof-of-principle trial in healthy volunteers to investigate safety, local tolerability, pharmacokinetics, and pharmacodynamics of Asacaine after topical administration on skin exposed to ultraviolet B radiation
Auxesis Pharma Holding AB (publ)1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年9月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Peter Åberg
Scientific
Auxesis Pharma Holding AB (publ)
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.Obesity2023-507758-34-00Rose Pharma Inc.12
招募中
不适用
A study to test whether different doses of BI 3000202 help people with systemic lupus erythematosus (SLE)Systemic lupus erythematosusjRCT2071250153405
招募中
不适用
A study to test how effective belumosudil tablets are for treating adult participants with chronic lung allograft dysfunction
(ROCKaspire)Lung transplant rejectionjRCT2031250734180
招募中
不适用
A Phase IIb dose-ranging study to assess the efficacy and safety of GIA632 in participants with non-segmental vitiligo (CGIA632B12201)Non-segmental Vitiligo (NSV)jRCT203126003020
招募中
1 期
A randomised, double-blind, placebo-controlled trial to assess the effects of EP395 following an inhaled endotoxin challenge in healthy adults2024-516187-29-00EpiEndo Pharmaceuticals ehf.65